- BioDuro has launched a new Business Unit focused on peptide drug discovery and development, integrating its chemistry, biology, DMPK, drug substance, and drug product capabilities.
- The unit is fully operational and led by Dr Fengping Xiao, who brings decades of experience across small molecules and peptides.
BioDuro has launched a new Business Unit (BU) dedicated to peptide drug discovery and development. The announcement highlights the company’s plan to strengthen its peptide technology platform to meet global demand for peptide-based therapeutics, including GLP-1 treatments.
The BU is already fully operational and will be led by Fengping Xiao, Ph.D. Dr Xiao has decades of experience spanning drug discovery and development across small molecules and peptides. The launch brings together the company’s chemistry, biology, drug metabolism and pharmacokinetics (DMPK), drug substance, and drug product capabilities.
BioDuro said the new structure integrates its existing peptide capabilities, including DNA-encoded library (DEL) screening and AI-enabled peptide design. The unit will operate as a specialised platform with cross-functional expertise, dedicated resources, and customised workflows.
“Our goal is to provide comprehensive scientific expertise and fully integrated solutions by bringing together the best minds and technologies to deliver optimal results for our global partners.”
Dr Xiao
“The creation of this Peptide BU marks a pivotal milestone for BioDuro,” added Armin Spura, Ph.D., Chief Executive Officer of BioDuro. “Our mission is to build the most advanced peptide platform, powered by exceptional science, state-of-the-art technology, and a world-class team, to meet the growing customer demand for complex peptide therapeutics worldwide.”
